Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian, Rebecca Ellwood, Olga Tatarinova, Graham David Rose, George Nteliopoulos, Gareth Gerrard, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD, Alistair Reid, BSc, PhD, Letizia Foroni, MD PhD, Richard Clark, MBBS, MRCP, MRCPath, MD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2018-99-117616

Published: 2018

Journal Articles

"Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets

Jamshid S Khorashad, MD PhD, Carme Ripoll Fiol, Eva Yebra-Fernandez, MD, Elisabet Nadal-Melsio, MD, Mahroo Karimpoor, PhD, Simone Claudiani, MD, Alistair Reid, BSc, PhD, Steven Knapper, DM, Kikkeri Naresh, Jane Apperley, MB ChB MD, Clinton C. Mason, PhD

Blood (2018) 132 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2018-99-115417

Published: 2018

Journal Articles

SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia

Dongqing Yan, Anthony D. Pomicter, MS, William L. Heaton, MS, Clint C. Mason, PhD, Jonathan Ahmann, BS, Anna Senina, MS, Anca Franzini, PhD, Brayden Halverson, Hein Than, MD FRCPath, MRCP, Phillip M. Clair, MS, Jamshid S Khorashad, MD PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 907.

https://doi.org/10.1182/blood-2018-99-115468

Published: 2018

Journal Articles

Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling

Anca Franzini, PhD, Jamshid S Khorashad, MD PhD, Hein Than, MD FRCPath, MRCP, Anthony D. Pomicter, MS, Dongqing Yan, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2018) 132 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2018-99-115077

Published: 2018

Journal Articles

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Simone Claudiani, MD, Jane Apperley, MB ChB MD, Afzal Khan, Richard Szydlo, PhD, George Nesr, MD, George Adams, MBChB, Letizia Foroni, MD PhD, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3007.

https://doi.org/10.1182/blood-2018-99-119602

Published: 2018

Journal Articles

Development of Foam-Based 3-Dimensional Culture to Investigate Drug Sensitivity in Primary Leukaemia Cells

Mahroo Karimpoor, PhD, Eva Yebra-Fernandez, MD, Maryam Parhizkar, PhD, Mine Orlu, Duncan Craig, PhD, Mohan Edirisinghe, PhD, Jamshid S Khorashad, MD PhD

Blood (2017) 130 (Supplement 1): 3824.

https://doi.org/10.1182/blood.V130.Suppl_1.3824.3824

Published: 2017

Journal Articles

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

Louise Caldwell, BSc, Simone Claudiani, MD, Dragana Milojkovic, MBBS, PhD, Richard Szydlo, PhD, Elisabetta Abruzzese, MD, George Nesr, MD, Michael J. Mauro, MD, Renuka Palanicawander, MD, Aoife Gatenby, BSc, Ira Sabli, BSc, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1612.

https://doi.org/10.1182/blood.V130.Suppl_1.1612.1612

Published: 2017

Journal Articles

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Simone Claudiani, MD, Adi Shacham Abulafia, Ira Sabli, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1628.

https://doi.org/10.1182/blood.V130.Suppl_1.1628.1628

Published: 2017

Journal Articles

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Simone Claudiani, MD, Aoife Gatenby, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, Emily Ching, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1629.

https://doi.org/10.1182/blood.V130.Suppl_1.1629.1629

Published: 2017

Journal Articles

MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Jamshid S. Khorashad, MD PhD, Anupriya Agarwal, PhD, Clinton C. Mason, PhD, Russell Bell, PhD, Anna Senina, MS, Anthony D. Pomicter, MS, Fan Yu, MD, Hannah M. Redwine, Amber D. Bowler, Phillip M. Clair, MS, Srinivas K. Tantravahi, MD, Shannon K. McWeeney, Brian J. Druker, MD, Derek L. Stirewalt, Vivian Oehler, MD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2016) 128 (22): 934.

https://doi.org/10.1182/blood.V128.22.934.934

Published: 2016

Journal Articles

MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Jamshid S. Khorashad, MD PhD, Anupriya Agarwal, PhD, Clinton C. Mason, PhD, Fan Yu, MD, Hannah M. Redwine, Amber D. Bowler, Kevin C. Gantz, Kimberly R. Reynolds, MS, Phillip M. Clair, MS, David J. Anderson, MBA, Srinivas K Tantravahi, Shannon K. McWeeney, PhD, Brian J. Druker, MD, Derek L. Stirewalt, MD, Vivian G. Oehler, MD, Thomas O'Hare, PhD, Michael W. Deininger

Blood (2015) 126 (23): 14.

https://doi.org/10.1182/blood.V126.23.14.14

Published: 2015

Journal Articles

Transition of Chronic Myeloid Leukemia to Chronic Myelomonocytic Leukemia As a Tool to Observe Development of Chronic Myelomonocytic Leukemia

Jamshid S Khorashad, MD PhD, Srinivas K Tantravahi, Dongqing Yan, PhD, Anna M. Eiring, PhD, Hannah M. Redwine, Amber D. Bowler, Kevin C. Gantz, Keith M Gligorich, PhD, Anthony D Pomicter, MS, Todd W Kelley, MD, Thomas O'Hare, PhD, Michael W Deininger, MD PhD

Blood (2015) 126 (23): 5223.

https://doi.org/10.1182/blood.V126.23.5223.5223

Published: 2015

Journal Articles

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival

Clinton C. Mason, PhD, Jamshid S. Khorashad, MD PhD, Srinivas K. Tantravahi, MD, Todd W. Kelley, MD, Anthony D. Pomicter, M.S., Anthony J. Iovino, Kimberly R. Reynolds, M.S., Anna M. Eiring, PhD, Matthew S. Zabriskie, BS, Zev Kronenberg, Jeffrey W. Tyner, Brian Dalley, PhD, Kim-Hien T. Dao, DO,PhD, Thomas O'Hare, PhD, Mark Yandell, PhD, Brian J. Druker, Jason R. Gotlib, MD, Michael W. Deininger

Blood (2014) 124 (21): 4637.

https://doi.org/10.1182/blood.V124.21.4637.4637

Published: 2014

Journal Articles

The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance

Anna M. Eiring, PhD, Anupriya Agarwal, Jamshid S. Khorashad, MD PhD, Clinton C. Mason, PhD, David J. Anderson, MBA, Fan Yu, MD, PhD, Hannah M. Redwine, Kevin C. Gantz, Kimberly R. Reynolds, M.S., Shannon K. McWeeney, Brian J. Druker, Thomas O'Hare, Michael W. Deininger

Blood (2014) 124 (21): 1786.

https://doi.org/10.1182/blood.V124.21.1786.1786

Published: 2014

Journal Articles

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Ira L. Kraft, BS, Brent D.G. Page, PhD, Tian Y. Zhang, MD, PhD, Jamshid S. Khorashad, MD, PhD, FRCPath, Nadeem A. Vellore, PhD, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Anna V. Senina, MS, Matthew S. Zabriskie, BS, Shazia Ahmad, Clinton C. Mason, PhD, Richard Moriggl, PhD, Riccardo Baron, PhD, Thomas O'Hare, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2013) 122 (21): 854.

https://doi.org/10.1182/blood.V122.21.854.854

Published: 2013

Journal Articles

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

Ira L Kraft, BS, Anna M. Eiring, PhD, Brent DG Page, BS, Clinton C Mason, PhD, Zhimin Gu, PhD, Jamshid S Khorashad, MD, PhD, David J Anderson, BA, Anthony D Pomicter, MS, Kimberly R Reynolds, MS, Johanna Estrada, Matthew S Zabriskie, BS, Patrick T Gunning, PhD, Thomas O'Hare, PhD, Michael W Deininger, MD, PhD

Blood (2012) 120 (21): 2445.

https://doi.org/10.1182/blood.V120.21.2445.2445

Published: 2012

Journal Articles

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Anna M. Eiring, PhD, Ira L Kraft, BS, Brent DG Page, BS, David J Anderson, BA, Zhimin Gu, PhD, Jamshid S Khorashad, MD, PhD, Anthony D Pomicter, MS, Kimberly R Reynolds, MS, Matthew S Zabriskie, BS, Richard Moriggl, PhD, Patrick T Gunning, PhD, Thomas O'Hare, PhD, Michael W Deininger, MD, PhD

Blood (2012) 120 (21): 31.

https://doi.org/10.1182/blood.V120.21.31.31

Published: 2012

Journal Articles

Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis

Ming Hu, PhD, Jamshid S Khorashad, MD, PhD, Aristeidis Chaidos, MD, PhD, Georgios Nteliopoulos, PhD, Mattaka Khongkow, Ms, Irene Roberts, John Goldman, DM, FRCP, FRCPath, FMedSci, Alistair Reid, PhD, Eric W-.F. Lam, PhD, Jane Apperley, Anastasios Karadimitris, MD, PhD

Blood (2012) 120 (21): 1215.

https://doi.org/10.1182/blood.V120.21.1215.1215

Published: 2012

Journal Articles

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Xiaoyan Jiang, MD, PhD, Hannah Grant, PhD, Justin Stebbing, MD, PhD, Letizia Foroni, MD, Charles Craddock, BM, MRCP, MRCPah, MD, Mike Griffiths, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, MD, PhD, Jamshid S. Khorashad, MD, PhD, Gareth Gerrard, MD, PhD, Lihui Wang, MD, PhD, Julie Irving, PhD, Meng Wang, PhD, Loraine Karran, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Donna L. Forrest, MD, Karen Page, MA, PhD, Connie J. Eaves, PhD, Adrian Woolfson, PhD

Blood (2010) 116 (21): 3397.

https://doi.org/10.1182/blood.V116.21.3397.3397

Published: 2010

NARROW

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

"Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets

SIRT5 As a Therapeutic Target in Acute Myeloid Leukemia

Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Development of Foam-Based 3-Dimensional Culture to Investigate Drug Sensitivity in Primary Leukaemia Cells

Changes in RT-qPCR Levels during and after TKI Interruptions for Attempted Conceptions in Women with CML

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia

MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia

Transition of Chronic Myeloid Leukemia to Chronic Myelomonocytic Leukemia As a Tool to Observe Development of Chronic Myelomonocytic Leukemia

Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival

The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Next-Generation STAT3 Inhibitors As Targeted Therapeutics in Chronic Myeloid Leukemia.

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only